Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ORPN

Bioblast Pharma (ORPN) Stock Price, News & Analysis

Bioblast Pharma logo

About Bioblast Pharma Stock (NASDAQ:ORPN)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$0.92
$1.03
50-Day Range
$11.50
$28.49
52-Week Range
$6.16
$30.00
Volume
89,776 shs
Average Volume
N/A
Market Capitalization
$399,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn's disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company is headquartered in Nes-Ziona, Israel.

Remove Ads
Receive ORPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bioblast Pharma and its competitors with MarketBeat's FREE daily newsletter.

ORPN Stock News Headlines

Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
See More Headlines

ORPN Stock Analysis - Frequently Asked Questions

Shares of Bioblast Pharma reverse split on Wednesday, March 6th 2019. The 1-8 reverse split was announced on Wednesday, March 6th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 5th 2019. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bioblast Pharma investors own include Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), SELLAS Life Sciences Group (SLS), Immunomedics (IMMU), Athersys (ATHX), ContraFect (CFRX) and Corbus Pharmaceuticals (CRBP).

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ORPN
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$7.56 per share
Price / Book
0.13

Miscellaneous

Free Float
N/A
Market Cap
$399,000.00
Optionable
Not Optionable
Beta
1.41
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:ORPN) was last updated on 4/2/2025 by MarketBeat.com Staff
From Our Partners